The Relationship Between GLUT-1 and Vascular Endothelial Growth Factor Expression and 18F-FDG Uptake in Esophageal Squamous Cell Cancer Patients

Kobayashi, Maiko; Kaida, Hayato; Kawahara, Akihiko; Hattori, Satoshi; Kurata, Seiji; Hayakawa, Masanobu; Hirose, Yasumitsu; Uchida, Masafumi; Kage, Masayoshi; Fujita, Hiromasa; Hayabuchi, Naofumi; Ishibashi, Masatoshi

doi:10.1097/rlu.0b013e31823924bb

Cited by 31 publications

(27 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increased glucose uptake is an acknowledged characteristic of cancer cells, and applying this feature when imaging tumors using radioactive tomography has become a diagnostic standard [18, 19]. However, no definite evidence distinguishes different types of glucose transporters that affect the glucose uptake from one another.…”

Section: Discussionmentioning

confidence: 99%

Predictive value of glucose transporter-1 and glucose transporter-3 for survival of cancer patients: A meta-analysis

et al. 2017

View full text Add to dashboard Cite

Background and ObjectiveThe role of glucose transporters in cancers remains contradictory. We conducted a systematic review and meta-analysis to assess the association between overall survival and glucose transporter s (GLUTs) 1 and 3 to find an accurate prognostic biomarker.MethodsWe systematically searched the PubMed, EMbase and Medline databases for relevant published studies that were consistent with the eligible criteria up to January 2016, and calculated pooled estimated hazard ratios of GLUT-1 and -3′s expressions in different cancer types and ethnic populations. Random-effects models were used to assess estimates from studies with significant heterogeneities.ResultsOverall, 12 studies concerning GLUT 1 and 2 studies concerning GLUT 3, which involved 2008 participants when combined, were included in this analysis. We found that overexpression of GLUTs were significantly correlated to poorer survival rates (HR=1.63, 95%CI=1.09-2.44 and HR=1.89, 95%CI=1.28-2.81). In the subgroup analysis, the GLUT 1 up-regulation was correlated with negative overall survival in pancreatic cancer and gastric cancer and with better overall survival in colorectal cancer. In addition, overexpression of GLUT 1 was associated with a poorer prognosis in the Asian population, while no significance was found in the non-Asian subgroup. However, limitations do exist, which could be handled better.ConclusionsA combination of GLUTs 1 and 3 might help predict malignancy of cancers and direct effective cancer therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Predictive value of glucose transporter-1 and glucose transporter-3 for survival of cancer patients: A meta-analysis

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Previous reports have suggested that GLUT1 has an important role in 18 F-FDG uptake in patients with lung cancer, soft tissue sarcoma and pancreatic cancer [9], [17], [18]. Conversely, Tohma et al reported low correlation between 18 F-FDG uptake and GLUT1 expression in esophageal cancer [19].…”

Section: Discussionmentioning

confidence: 99%

“…Therefore, many studies have focused on defining the relationship between FDG uptake and the expression of tumor biomarkers, including nuclear- associated antigen Ki-67, cyclooxygenase-2 (Cox-2), vascular endothelial growth factor (VEGF) and the glucose transporter 1 (GLUT1) in relation to lung cancer [4], [8], [9]. To date, these have reported a correlation between SUV max and tumor biomarkers and have contributed to understanding the Warburg effect and identifying tumor-related genes that are associated with the SUV, thereby providing a robust basis for staging, prognosis and personalized treatment of cancers.…”

Section: Introductionmentioning

confidence: 99%

TIGAR Is Correlated with Maximal Standardized Uptake Value on FDG-PET and Survival in Non-Small Cell Lung Cancer

Zhou

Xie

et al. 2013

PLoS ONE

View full text Add to dashboard Cite

ObjectiveEvaluation of 18F-FDG uptake value via PET is central to current methods of diagnosis and staging of non-small cell lung cancer (NSCLC) due to its ability to evaluate expression levels of key regulators associated with glucose metabolism in tumor cells. Tp53-induced glycolysis and apoptosis regulator (TIGAR) is an important P53-induced protein that can inhibit glycolysis; however, there have been few clinical studies on its mechanism. Here we have investigated the relationship between TIGAR expression and 18F-FDG PET in tumors, along with its relationship with the clinical characteristics of NSCLC.MethodsWe analyzed SUVmax in 79 patients with NSCLC through immunohistochemical staining of TIGAR and five other biological markers associated with tumor cell glycolysis, in order to evaluate the correlation between their expression and SUVmax. We also plotted Kaplan-Meier survival curves to assess TIGAR expression with the prognosis and survival of patients with NSCLC.ResultsThe key findings were as follows: SUVmax was negatively correlated with the expression of TIGAR (r = −0.31, p<0.01); TIGAR expression was correlated with tumor size (p = 0.01), histological type (p<0.01), differentiation degree (p<0.01) and lymph node metastasis(p<0.01) in patients with NSCLC; and the survival time of patients whose TIGAR was negatively expressed was significantly shorter than for those whose TIGAR was positively expressed (P = 0.023).ConclusionsThe expression of TIGAR in primary tumors is significantly correlated with SUVmax, and low expression of TIGAR may predict a worse clinical outcome in patients with NSCLC.

show abstract

“…Increased glucose uptake is a well-known feature of cancer cells, and is widely used to image tumors using radioactively labeled glucose in positron emission tomography, which is, for example, part of the diagnostic standard in lung cancer [4,15]. The glucose uptake capacity of cells largely depends on the expression of glucose transporters, which transport glucose across membranes.…”

Section: Discussionmentioning

confidence: 99%

Glucose transporters 1, 3, 6, and 10 are expressed in gastric cancer and glucose transporter 3 is associated with UICC stage and survival

et al. 2015

View full text Add to dashboard Cite

Background Due to proliferation and increased metabolism, cancer cells have high glucose requirements. The glucose uptake of cells is influenced by a group of membrane proteins denoted the glucose transporter family (Glut-1 to -12). Whereas increased expression and a negative correlation with survival have been described for Glut-1 in several types of cancer, the impact of other glucose transporters on tumor biology is widely unknown. Methods In this retrospective study, gastric cancer specimens of 150 patients who underwent total gastrectomy between 2005 and 2010 were stained for Glut-1, -3, -6, and -10 by immunohistochemistry. Expression of Glut-1, -3, -6, and 10 was correlated to prognosis as well as clinical and pathological parameters. Results Glut-1, Glut-3, Glut-6, and Glut-10 were expressed in 22.0, 66.0, 38.0, and 43.3 % of the analyzed samples. Whereas Glut-1, -6, and -10 did not show a correlation with prognosis, positive staining for Glut-3 was associated with higher UICC stage and inferior prognosis. The mean overall survival was 38.6 months for Glut-3 positive patients, as compared to 51.2 months for Glut-3 negative patients (p \ 0.05). Coexpression of two or more of the analyzed glucose transporters was correlated to inferior prognosis. Glut-3 and UICC stage were significant prognostic factors in multivariate analysis. Conclusions All of the analyzed glucose transporters were expressed in a significant proportion of the gastric cancer samples. Glut-3 was associated with higher UICC stage and inferior prognosis. These findings are relevant to therapeutic approaches that target glucose metabolism as well as to imaging using radioactively labeled glucose.

show abstract

The Relationship Between GLUT-1 and Vascular Endothelial Growth Factor Expression and 18F-FDG Uptake in Esophageal Squamous Cell Cancer Patients

Abstract: (18)F-FDG uptake can be determined by GLUT-1 and VEGF. SUV(max) would have a connection with the tumor progression and lymph node metastasis.

Cited by 31 publications

References 29 publications

Predictive value of glucose transporter-1 and glucose transporter-3 for survival of cancer patients: A meta-analysis

Predictive value of glucose transporter-1 and glucose transporter-3 for survival of cancer patients: A meta-analysis

TIGAR Is Correlated with Maximal Standardized Uptake Value on FDG-PET and Survival in Non-Small Cell Lung Cancer

Glucose transporters 1, 3, 6, and 10 are expressed in gastric cancer and glucose transporter 3 is associated with UICC stage and survival

Contact Info

Product

Resources

About